Indenoisoquinolinone analogs and methods of use thereof
    1.
    发明授权
    Indenoisoquinolinone analogs and methods of use thereof 失效
    茚并异喹啉酮类似物及其使用方法

    公开(公告)号:US08119654B2

    公开(公告)日:2012-02-21

    申请号:US12039611

    申请日:2008-02-28

    IPC分类号: A61K31/473 C07D221/18

    摘要: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

    摘要翻译: 本发明涉及茚并异喹啉酮类似物,包含有效量的茚并异喹啉酮类似物和治疗或预防炎性疾病,再灌注损伤,糖尿病,糖尿病并发症,器官移植引起的再氧化损伤,缺血状况, 神经变性疾病,肾衰竭,血管疾病,心血管疾病,癌症,早产儿并发症,心肌病,视网膜病变,肾病,神经病,勃起功能障碍或尿失禁,包括向有需要的受试者施用有效量的茚并异喹啉酮类似物 。

    Indenoisoquinolinone Analogs and Methods of Use Thereof
    2.
    发明申请
    Indenoisoquinolinone Analogs and Methods of Use Thereof 失效
    茚并异喹啉酮类似物及其使用方法

    公开(公告)号:US20100004220A1

    公开(公告)日:2010-01-07

    申请号:US12039611

    申请日:2008-02-28

    摘要: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

    摘要翻译: 本发明涉及茚并异喹啉酮类似物,包含有效量的茚并异喹啉酮类似物和治疗或预防炎性疾病,再灌注损伤,糖尿病,糖尿病并发症,器官移植引起的再氧化损伤,缺血状况, 神经变性疾病,肾衰竭,血管疾病,心血管疾病,癌症,早产儿并发症,心肌病,视网膜病变,肾病,神经病,勃起功能障碍或尿失禁,包括向有需要的受试者施用有效量的茚并异喹啉酮类似物 。

    Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
    4.
    发明授权
    Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof 有权
    嘌呤衍生物作为腺苷A1受体激动剂及其使用方法

    公开(公告)号:US07423144B2

    公开(公告)日:2008-09-09

    申请号:US11137632

    申请日:2005-05-25

    摘要: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

    摘要翻译: 本发明涉及嘌呤衍生物; 包含有效量的嘌呤衍生物的组合物; 以及降低动物代谢率的方法,保护动物的心脏免受心脏停搏期间的心肌损伤; 或用于治疗或预防心血管疾病,神经障碍,缺血状况,再灌注损伤,肥胖症,消耗性疾病或糖尿病,包括向有需要的动物施用有效量的嘌呤衍生物。

    Method of reducing intraocular pressure in humans
    7.
    发明授权
    Method of reducing intraocular pressure in humans 有权
    降低人眼内压的方法

    公开(公告)号:US08476247B2

    公开(公告)日:2013-07-02

    申请号:US13072349

    申请日:2011-03-25

    摘要: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).

    摘要翻译: 本文提供了使用N6-环戊基腺苷(CPA),CPA衍生物或前药或CPA增强的角膜通透性制剂降低人眼内压(IOP)的方法。 在一个实施方案中,本发明涉及可透过角膜的CPA衍生物或前药。 在另一个实施方案中,本发明涉及某些化合物在人受试者中用于减少和/或控制治疗青光眼或高眼压症(OHT)的升高或异常波动的IOP的用途。

    Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
    8.
    发明授权
    Purine derivatives as adenosine A1 receptor agonists and methods of use thereof 有权
    嘌呤衍生物作为腺苷A1受体激动剂及其使用方法

    公开(公告)号:US08183224B2

    公开(公告)日:2012-05-22

    申请号:US12221539

    申请日:2008-08-04

    IPC分类号: A61K31/7076 C07H19/167

    摘要: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

    摘要翻译: 本发明涉及嘌呤衍生物; 包含有效量的嘌呤衍生物的组合物; 以及降低动物代谢率的方法,保护动物的心脏免受心脏停搏期间的心肌损伤; 或用于治疗或预防心血管疾病,神经障碍,缺血状况,再灌注损伤,肥胖症,消耗性疾病或糖尿病,包括向有需要的动物施用有效量的嘌呤衍生物。

    Tetracyclic Sulfonamide Compounds and methods of use thereof
    10.
    发明申请
    Tetracyclic Sulfonamide Compounds and methods of use thereof 审中-公开
    四环磺酰胺化合物及其使用方法

    公开(公告)号:US20060287311A1

    公开(公告)日:2006-12-21

    申请号:US11354706

    申请日:2006-02-15

    摘要: The present invention relates to Tetracyclic Sulfonamide Compounds, compositions comprising an effective amount of a Tetracyclic Sulfonamide Compound and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, Parkinson's disease, renal failure, a vascular disease, a cardiovascular disease, or cancer, comprising administering to a subject in need thereof an effective amount of a Tetracyclic Sulfonamide Compound.

    摘要翻译: 本发明涉及四环磺酰胺化合物,包含有效量的四环磺酰胺化合物的组合物和治疗或预防炎性疾病,再灌注损伤,糖尿病,糖尿病并发症,器官移植引起的再氧化损伤,缺血状况, 帕金森病,肾衰竭,血管疾病,心血管疾病或癌症,包括向有需要的受试者施用有效量的四环磺酰胺化合物。